- Home
- LIDR vs NEUP Comparison
LIDR vs NEUP Comparison
Compare LIDR & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIDR
- NEUP
- Stock Information
- Founded
- LIDR 2013
- NEUP 1996
- Country
- LIDR United States
- NEUP United States
- Employees
- LIDR N/A
- NEUP N/A
- Industry
- LIDR Auto Parts:O.E.M.
- NEUP
- Sector
- LIDR Consumer Discretionary
- NEUP
- Exchange
- LIDR Nasdaq
- NEUP Nasdaq
- Market Cap
- LIDR 14.8M
- NEUP 12.7M
- IPO Year
- LIDR N/A
- NEUP N/A
- Fundamental
- Price
- LIDR $0.77
- NEUP $6.87
- Analyst Decision
- LIDR Hold
- NEUP Strong Buy
- Analyst Count
- LIDR 1
- NEUP 1
- Target Price
- LIDR N/A
- NEUP $21.00
- AVG Volume (30 Days)
- LIDR 463.9K
- NEUP 29.5K
- Earning Date
- LIDR 08-04-2025
- NEUP 06-17-2025
- Dividend Yield
- LIDR N/A
- NEUP N/A
- EPS Growth
- LIDR N/A
- NEUP N/A
- EPS
- LIDR N/A
- NEUP 0.00
- Revenue
- LIDR $246,000.00
- NEUP $15,662,715.00
- Revenue This Year
- LIDR $2,677.23
- NEUP N/A
- Revenue Next Year
- LIDR $409.09
- NEUP N/A
- P/E Ratio
- LIDR N/A
- NEUP $4,008.24
- Revenue Growth
- LIDR N/A
- NEUP N/A
- 52 Week Low
- LIDR $0.49
- NEUP $2.90
- 52 Week High
- LIDR $4.30
- NEUP $126.00
- Technical
- Relative Strength Index (RSI)
- LIDR 58.46
- NEUP N/A
- Support Level
- LIDR $0.68
- NEUP N/A
- Resistance Level
- LIDR $0.84
- NEUP N/A
- Average True Range (ATR)
- LIDR 0.06
- NEUP 0.00
- MACD
- LIDR 0.00
- NEUP 0.00
- Stochastic Oscillator
- LIDR 60.70
- NEUP 0.00
About LIDR AEye Inc.
AEye Inc is a provider of high-performance, active lidar systems for vehicle autonomy, driver-assistance systems (ADAS), and robotic vision applications. The company's software-definable 4Sight Intelligent Sensing Platform combines solid-state active lidar, an optionally fused low-light HD camera, and integrated deterministic artificial intelligence to capture more intelligent information with less data, enabling faster, more accurate, and more reliable perception of the surroundings. Majority of the Company's revenue is generated from customers located in the United States followed by Europe, and Asia-Pacific.
About NEUP Neuphoria Therapeutics Inc. Common Stock
Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.